DeutschNewstral
Article
bizjournals.com on 2020-10-28 19:22
FDA grants two key designations to Passage Bio's experimental Krabbe disease therapy
Related news
- Annovis Bio's stock takes a ride following positive study results for experimental Parkinson's therapybizjournals.com
- FDA rejects AstraZeneca's experimental diabetes therapybizjournals.com
First FDA-approved genetic therapy fights leukemiaengadget- BFDA Ousts Spokeswoman After Covid Therapy Misstatementsbloomberg.com
FDA Talks Regenerative Medicine Advanced Therapy Designationjdsupra.com- FDA Adjustment to Orphan Drug Review May Indicate Increased Scrutiny of Designationsjdsupra.com
FDA to Ease Some Cancer Patients’ Access to Experimental Drugswsj.com
FDA skeptical of benefits from experimental ALS druglasvegassun.com
FDA advisers vote against experimental ALS treatment pushed by patientsSeattle Times
Experimental hormone therapy may speed recovery for COVID patientsStar Tribune
Experimental gene therapy points to cure for rare immune diseasenewatlas.com- FDA grants emergency approval to experimental COVID-19 antibody therapynewatlas.com
Trump quickly approves experimental plasma therapy, despite scientists' doubtsSydney Morning Herald
FDA approves gene therapy for a type of blindnessKOAT 7
Seeing hope: FDA panel considers gene therapy for blindnessWBNS-10TV- FDA approves Spark Therapeutics' gene therapy treatment; pricing questions remainbizjournals.com
- FDA Seizes Stem Cell Therapy—A First of Many?jdsupra.com
FDA advisers endorse gene therapy to treat form of blindnessdecaturdaily.com